Novo Nordisk ADR (NYSE: NVO) kicked off on Friday, down -3.40% from the previous trading day, before settling in for the closing price of $105.32. Over the past 52 weeks, NVO has traded in a range of $94.73-$148.15.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 14.25% over the last five years. While this was happening, its average annual earnings per share was recorded 21.42%. With a float of $3.34 billion, this company’s outstanding shares have now reached $3.38 billion.
The firm has a total of 63370 workers. Let’s measure their productivity. In terms of profitability, gross margin is 84.66%, operating margin of 43.96%, and the pretax margin is 44.07%.
Novo Nordisk ADR (NVO) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Drug Manufacturers – General Industry. The insider ownership of Novo Nordisk ADR is 0.02%, while institutional ownership is 10.04%.
Novo Nordisk ADR (NVO) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 21.42% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 11.00% during the next five years compared to 16.48% growth over the previous five years of trading.
Novo Nordisk ADR (NYSE: NVO) Trading Performance Indicators
Take a look at Novo Nordisk ADR’s (NVO) current performance indicators. Last quarter, stock had a quick ratio of 0.75. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 8.64. Likewise, its price to free cash flow for the trailing twelve months is 29.97.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 3.08, a number that is poised to hit 0.89 in the next quarter and is forecasted to reach 4.10 in one year’s time.
Technical Analysis of Novo Nordisk ADR (NVO)
Analysing the last 5-days average volume posted by the [Novo Nordisk ADR, NVO], we can find that recorded value of 5.16 million was better than the volume posted last year of 4.46 million. As of the previous 9 days, the stock’s Stochastic %D was 14.33%. Additionally, its Average True Range was 2.68.
During the past 100 days, Novo Nordisk ADR’s (NVO) raw stochastic average was set at 3.11%, which indicates a significant decrease from 10.57% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 28.07% in the past 14 days, which was lower than the 34.47% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $118.58, while its 200-day Moving Average is $128.19. Now, the first resistance to watch is $102.61. This is followed by the second major resistance level at $103.49. The third major resistance level sits at $104.63. If the price goes on to break the first support level at $100.59, it is likely to go to the next support level at $99.45. Now, if the price goes above the second support level, the third support stands at $98.57.
Novo Nordisk ADR (NYSE: NVO) Key Stats
The company with the Market Capitalisation of 339.65 billion has total of 4,487,532K Shares Outstanding. Its annual sales at the moment are 33,724 M in contrast with the sum of 12,151 M annual income. Company’s last quarter sales were recorded 10,511 M and last quarter income was 4,024 M.
